Point Roberts, WA - December 4, 2012 (Investorideas.com Newswire)
Investorideas.com, an investor research portal specializing in sector
research for independent investors publishes CFA commentary on Decision
Diagnostics Corp. (
OTCBB: DECN), by Patrick J. Murphy of Murphy Analytics LLC, a provider of sponsored research coverage on smallcap stocks.
Decision Diagnostics Corp. (
OTCBB: DECN)
Patrick J. Murphy
Decision Diagnostics Corp. is developing products that offer unique
solutions in medical care. The Shasta GenStrip® is an at home
diagnostic for testing blood glucose designed to run on the Johnson
& Johnson's (NYSE: JNJ) LifeScan LifeFirst™ OneTouch® family of
meters, which are used by over 5 million people in the U.S. alone and
for which JNJ estimates 97% of patients, including those with Medicare,
are insured.
Of the products developed by DECN, the Company's Shasta GenStrip®
in particular has significant potential for helping the rapidly growing
diabetic population. DECN reports that the application for the Shasta
GenStrip® was submitted to the FDA in December of 2010, and although the
approval process typically now takes in excess of two years, DECN is
now responding to a short series of follow up questions from the FDA,
subsequent to recent meetings.
| Select Stock Trading Data |
| Recent Stock Price: |
$0.17 |
| Shares Outstanding: |
11.48 million |
| Float |
8.4 million |
| Recent Market Cap: |
$1.95 million |
| 52 Week Range: |
$0.05 - $0.65 |
| Exchange: |
OTCBB |
| Ticker: |
DECN |
| URL: |
http://www.decisiondiagnostics.com/ |
| Data sourced from Yahoo! Finance; otcbb.com; Company filings |
In terms of the overall market opportunity, a report from Research and Markets
estimates that the global blood glucose monitoring market was estimated
to be worth $8.9 billion in 2010 and is expected to grow 4.5% annually
to reach $12.2 billion, with blood glucose test strips representing
nearly 90% of the market at $10.9 billion. The report also cites
International Diabetes Federation that diabetes affected 366 million
people in 2011, or 8.3% of the global population, and that this is
projected to increase to 9.9% of the population by 2030.
Trends in the U.S. serve to illustrate what is driving the increase
in diabetes - the rise in obesity. According to the American Diabetes
Association , approximately 26 million people in the U.S. have diabetes,
representing 8.3% of the population, with 1.9 million new cases in
2010. The high prevalence of diabetes is not surprising in light of the
data
from the Centers for Disease Control (CDC) , which reports that during
the past 20 years, there has been a dramatic increase in obesity in the
United States and rates remain high at nearly 36% of U.S. adults and
approximately 17% of children and adolescents aged 2—19. Similarly,
metabolic syndrome affects nearly 50 million people in the U.S. Alone:
As addressed by the National Institute of Health:
"Metabolic syndrome is a name for a group of risk factors that
occur together and increase the risk for coronary artery disease,
stroke, and type 2 diabetes. Metabolic syndrome is becoming more and
more common in the United States. Researchers are not sure whether the
syndrome is due to one single cause, but all of the risks for the
syndrome are related to obesity.”
Unlike many competing product offerings, Genstrip employs a razor
blade only model, a diagnostic test strip, and DECN has stated that the
product is likely to cost less than 50% of the branded product without
sacrificing quality. As an illustration of the potential appetite for
the Genstrip product, DECN's 10-Q notes that the Company was approached
by the largest retailer in the world, recently revealed to be Wal-Mart
by DECN President and CFO Keith Berman, regarding the sale of Genstrip
at its 5,000+
stores
globally. DECN reports that a contract was negotiated in September 2010
and subsequently renegotiated and renewed in April 2011. However, while
conducting market research during this time and seeking pre-orders,
DECN reports that initial market interest was greater than the product
capacity of the Company's contract manufacturer, and the Company ended
the pre-order initiative while remaining confident there is a very large
opportunity for Genstrip in a market dominated by four large
pharmaceutical manufacturers which DECN reports sell similar products at
similar pricing.
It seems reasonable to speculate increasing prosperity around the
world is creating greater disposable income for increasing segments of
the population, with increasing leisure time and presumably less manual
labor. Whatever the cause or causes may be, the trend towards an
increase in obesity and a resulting increase in the diabetes population
seems clear, as does the potential opportunity for products that serve
that market. Although FDA approval is of course not a certainty, DECN
seems to have developed a product with significant potential if approval
is obtained.
DECN also has developed a line of medical
IT products
for the rapidly expanding EMR/HER market. Unlike other medical
information systems using standard computer terminals, Decision
Diagnostics Corp. uses smart phones, which allow physicians to carry,
access and update their patients' histories, medication data, and best
care guidelines - all at the point of care. Decision Diagnostics Corp.
is a provider of prescription drugs, home testing products for the
chronically ill, a fulfillment provider of direct to patient diabetes
programs, and a developer of cutting edge cell phone centric e-health
products and technologies.
Patrick Murphy Bio:
Patrick J. Murphy is the owner of Murphy Analytics LLC, a provider
of sponsored research coverage on smallcap stocks. Mr. Murphy has nearly
20 years of capital markets experience providing institutional
investment and transaction analysis across a range of asset classes
including microcap equities, commercial real estate debt and equity,
municipal derivatives and public finance, venture capital, fixed income,
CMBS and mortgage REIT's. In addition to his work with Murphy
Analytics, Mr. Murphy also serves as a consultant to a municipal
derivatives advisory firm. Mr. Murphy is an alumnus of the University of
Notre Dame (1991), with an undergraduate degree in Economics, and
earned a Masters Degree in Finance from St. Louis University in 1997.
Mr. Murphy is a CFA Charterholder and a member of the CFA Society of St.
Louis.
Patrick Murphy Disclaimer:
Readers are advised that the above article is solely for
information purposes and should not to be construed as an offer to sell
or the solicitation of an offer to buy any security. The views expressed
herein are based upon the author's analysis of the issuer's public
disclosures, and assumes both their accuracy and completeness. The
opinions and statements included herein are based on sources (including
the companies discussed and public sources) believed to be reliable and
in good faith, but no representation or warranty, express or implied, is
made as to their accuracy, completeness or correctness. The author has
not independently verified the information contained herein. This
information is not intended to be used as the sole basis of any
investment decisions, nor should it be construed as advice designed to
meet the investment needs of any particular investor. You should review a
complete information package on all companies, which should include,
but not be limited to, the Company's annual report, quarterly reports,
press releases and all regulatory filings. The foregoing discussion
contains statements which are based on current expectations, estimates
and projections, and differences from such expectations, estimates and
projections can be expected. The author, Patrick Murphy, was compensated
$500 by InvestorIdeas.com for writing this article. Murphy does not own
shares of any of the companies mentioned in this article. Mr. Murphy's
research firm, Murphy Analytics, may be engaged for the provision of a
research report on the Company in the future.
Decision Diagnostics Company websitehttp://www.decisiondiagnostics.com/
DECN SEC quarterly file
http://biz.yahoo.com/e/120820/decn10-q.html
More info on DECN at Investorideas.com
http://www.investorideas.com/CO/DECN/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector,
featuring stock news, commentary and trading alerts in leading sectors
including biotech, tech, mining, energy, water, renewable energy,
beverage stocks and more.
Follow Investorideas.com on Twitter
http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook
http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at
http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The Investorideas.com is a
third party publisher of news and research Our sites do not make
recommendations, but offer information portals to research news,
articles, stock lists and recent research. Nothing on our sites should
be construed as an offer or solicitation to buy or sell products or
securities. This site is currently compensated by featured companies,
news submissions and online advertising.
Disclosure: Investorideas.com has been compensated one hundred
fifty thousand shares for news and content publication and distribution
for 45 days
http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source -
www.Investorideas.com
http://www.lifescan.com/about-us
http://www.onetouch.com/onetouch-diabetes-testing-supplies
http://www.pharmpro.com/News/2011/05/Animas-and-LifeScan-Strengthen-Strategic-Focus-to-Better-Serve-People-Living-with-Diabetes/
http://www.investorideas.com/CO/DECN/news/2012/11211.asp
http://www.businesswire.com/news/home/20120111006216/en/Research-Markets-Blood-Glucose-Test-Strips-Market
http://www.diabetes.org/diabetes-basics/diabetes-statistics/?loc=DropDownDB-stats
http://www.cdc.gov/obesity/data/facts.html
http://www.ncbi.nlm.nih.gov/pubmed/17893688
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004546/
http://www.investorideas.com/CO/DECN/news/2012/11281.asp
Full news: http://www.investorideas.com/CO/AEMD/news/2012/12031.asp
* Silver Equivalency based on a Ag:Au ratio of 50:1. All numbers are uncut and rounded.
Source: 
About MWW Automotive Group (OTCQB: MWWC)
About Sunwin Stevia International, Inc. 
About NASDAQ 
Gulfport Energy Corporation is an Oklahoma City-based independent
oil and natural gas exploration and production company with its
principal producing properties located along the Louisiana Gulf Coast.
Gulfport has also acquired acreage positions in the Utica Shale of
Eastern Ohio and the Niobrara Formation of Western Colorado. In
addition, Gulfport holds a sizeable acreage position in the Alberta Oil
Sands in Canada through its interest in Grizzly Oil Sands ULC and has
interests in entities that operate in the Permian Basin in West Texas
and in Southeast Asia, including the Phu Horm gas field in Thailand.